Generic League - Market Analysis and Forecasts, 2007-2012, 2017 & 2022

Table of Contents

1. Executive Summary

2. An Overview of The Leading Generics Producers in 2007

• 2.1 Generics Medicines Experience Significant Growth in 2006
• 2.2 Teva Records Largest Sales of Generic Pharmaceuticals Globally in 2006

3 The World Generics Market

• 3.1 The World Generics Market to Grow by over 12% Per Annum to 2010
• 3.2 Top 20 Companies To Lose Leading Products To Generic Competition
• 3.3 Price is the Principal Competing Factor in the Generics Market
• 3.4 Countries with Lowest Branded Drug Prices have the Highest Generic Growth
• 3.5 Patent Expiration is the Major Driver in All Generic Markets
• 3.6 The US Has The Largest Generics Market
• 3.7 The UK has the Highest Generic Penetration by Value in All European Markets
• 3.8 Japan An Isolated Case in the Generic Market

4. The US and European Regulation of Generic Drugs

• 4.1 Generic Pharmaceuticals in the US Market
  • 4.2.1 The Hatch-Waxman Title I,
    • 4.2.1.1 US Congress First To Market 180-Day Exclusivity Period Incentive
    • 4.2.1.2 Bioequivalence An FDA Requirement
• 4.3 The Hatch-Waxman Act Title II has Promoted Innovation in the Branded Pharmaceutical Industry
• 4.4 The Hatch-Waxman Act Drives Influx Of Generic Pharmacuticals Significantly
• 4.5 Marked Difference In European Generics Patents Laws In Comparison With The US
• 4.6 European Generic Drug Development: Variation Between European Countries
• 4.7 EU Benefits From Long Data Exclusivity Protecting Patents
• 4.8 Additional EU Patent Protection is Afforded by Supplementary Protection Certificates
• 4.9 Compulsory Licensing Allows Generic Manufacture Before Patent Expiry
• 4.10 The WHO and Compulsory Licenses
• 4.11 Compulsory Licenses and the TRIPs Agreement
• 4.12 The Benefit of Being the First Generic to Market
• 4.12 The Advatages of First-to-Market Generics
• 4.13 Biogenerics A Continuously Expanding Market
• 4.14 Bioequivalence A Growing Concern For The Biogenerics Industry
• 4.15 US Biogenerics Regulatory Framework Awaits The Implementation of New Bills
• 4.16 European Drug Regulation Framework
• 4.17 European Medicines Agency (EMEA) Amends Its Biogeneric Regulation

5 TEVA Pharmaceutical Industries

• 5.1 Teva is Listed on Various Stock Exchanges, Including NASDAQ
• 5.2 Teva Achieved Sales of $8.4bn in 2006
  • 5.2.1 Most of Teva' s Sales are In North America
  • 5.2.2 Most of Teva' s Sales Are Generated by the Pharmaceuticals Division
  • 5.2.3 Vision and Core Values in Teva
• 5.3 Human Pharmaceuticals Division
  • 5.3.1 Teva Produces Generic Drugs in All Major Therapeutic Categories
  • 5.3.2 Teva Markets and Develops Innovative Drugs for Specialised Markets
  • 5.3.3 The Pharmaceuticals Division Contributes 90% of Teva' s Revenues
  • 5.3.4 Copaxone (glatiramer acetate)
  • 5.3.5 Azilect (rasagiline)
• 5.4 Active Pharmaceutical Ingredients (API) Division
• 5.5 Teva USA
• 5.6 Veterinary Products
• 5.7 Key Acquisitions by Teva
  • 5.7.1 Acquisition of Ivax Corporation in January 2006
  • 5.7.2 Sicor became a wholly owned subsidiary of Teva in January 2004
  • 5.7.3 Acquisition of Novopharm
• 5.8 A Brief History of Teva
  • 5.8.1 Formation of the Company at the Start of the Twentieth Century
  • 5.8.2 Growth During the WWII and the Establishment of the State of Israel during 1940s & 50s
  • 5.8.3 Consolidation During the 1960s & 70s Establishment of Teva Pharmaceutical Industries Ltd
  • 5.8.4 Further Acquisitions and Dominance During the 1980s
  • 5.8.5 1990s: Expanding Presence Worldwide
• 5.9 Teva Benefited from an Ambitious Strategy of Acquisition
• 5.10 Teva Had Over 150 Products Awaiting FDA Approval at the End of 2006
• 5.11 Promising First Quarter Results for 2007
• 5.12 Copaxone - Teva' s First Innovative Drug to Receive FDA Approval
• 5.12 Copaxone - Teva' s First Innovative Drug to Receive FDA Approval
  • 5.12.1 Steady Revenue Increase Expected for Teva' s Flagship Product
    • 5.12.1.1 Copaxone A Unique Immunomodulator Therapy For The Treatment of Relapsing-Remitting Multiple Sclerosis.
  • 5.12.2 Copaxone Faces Present and Future Competitive Challenges in the Market
  • 5.12.3 Copaxone Was Originally Licensed from the Weizmann Institute of Science
  • 5.12.4 Copaxone is the Subject of Promising Clinical Studies
  • 5.12.5 Lifecycle Management of Copaxone: Teva Makes Good Use of Collaborations
• 5.13 Azilect - Teva' s Recently Launched Innovative Product
  • 5.13 1 Azilect is Currently In a Period of High Early Growth
  • 5.13.2 Azilect is a Potent Agent for Early and Advanced Parkinson' s Disease
  • 5.13.3 Azilect Benefits from Convenient Dosing
  • 5.13 4 Azilect is Co-Marketed in Europe by Lundbeck and Teva
  • 5.13.5 Co-Development of Azilect with Eisai
  • 5.13.6 Phase IV Post-Marketing Study to Investigate Risk of Melanoma
  • 5.13.7 Azilect May Have Potential in the Early Treatment of Parkinson' s
  • 5.13.8 Competition for Azilect
  • 5.13.9 Azilect Has Performed Well in Clinical Studies
• 5.14 Teva Has a Diverse Generics Portfolio
  • 5.14.1 Revenues from Generics Spread Over Many Products
  • 5.14.2 Teva Receives First US Approval For Generic Uniretic Tablets
  • 5.14.3 Teva Receives Approval For Generic Dostinex Tablets
  • 5.15.4 Teva Announced Approval of Alprazolam ER Tablets
  • 5.14.5 Teva Announced Its Launch of Generic Wellbutrin XL Tablets Through Agreement With Anchen And IMPAX
  • 5.14.6 Teva Announced Tentative Approval Of Sumatriptan Succinate Tablets
  • 5.14.7 Teva Receives Approval for Generic Focalin Tablets
  • 5.14.8 Teva Announced Agreement with Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin
  • 5.14.9 Launch of Generic Zoloft by Teva
  • 5.14.10 Final Approval of Venlafaxine HCL Tablets
  • 5.14.11 Final Approval of Meloxicam Tablets
  • 5.14.12 Tentative Approval of Generic Lotrel
  • 5.14.13 Approval of Generic Zocor
  • 5.14.14 Teva Received First FDA Approval for Generic Proscar Tablets
  • 5.14.15 Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets
  • 5.14.16 Tentative Approval for Generic Cozaar Tablets
  • 5.14.17 Tentative Approval of Simvastatin Tablets
  • 5.14.18 Approval of Generic Lexapro Tablets
• 5.15 The Integration of Ivax' s Operations Greatly Increased Teva' s Strengths in Respiratory Drugs
• 5.16 Teva Pharmaceutical Market Forecast 2008-2013 & 2023
• 5.17 Pipeline Developments in Teva
  • 5.17 1 Teva is Conducting R&D in Important Therapeutic Areas
  • 5.17.2 Teva' s Investment in R&D Has Been Rising in Recent Years
  • 5.17.3 As a Leading Generic Producer Teva Has Progressed into Innovative Research & Development
• 5.18 Teva Has a Very Strong Generics Pipeline in Addition to Innovative Developments
  • 5.18.1 R&D Focussed on Multiple Sclerosis, Autoimmune Diseases, Neurology and Oncology
  • 5.18.2 Teva R&D is Concentrated in Four Divisions
• 5.19 Antineoplastics/Immunomodulating Agents
  • 5.19.1 Stemex Cell Therapy
  • 5.19.2 HMN 214
  • 5.19.3 EDRATIDE (TV 4710)
  • 5.19.4 SAIK-MS
  • 5.19.5 LMB 9
  • 5.19.6 Cervene (TP 38)
• 5.20 Central Nervous System Agents
  • 5.20.1 Citicoline (IP 302)
  • 5.20.2 Cladribine (NSC 105014F)
  • 5.20.3 Fampridine-SR
  • 5.20.4 Ladostigil
  • 5.20.5 Valrocemide
• 5.21 Genitourinary System/Sex Hormones
• 5.22 Respiratory System Agents
  • 5.22.1 Respicort
  • 5.22.2 Other Agents in Development
• 5.23 Licensing Deal With Vaccinex for Monoclonal Antibody
• 5.24 Teva Collaborates on Protalix' s Recombinant Plant Cell Expression Technology
• 5.25 Teva And Procognia (Israel) Ltd. Sign an Exclusive Collaboration Agreement for the Development of Biopharmaceuticals

6 Novartis' Sandoz

• 6.1 Sandoz is a Leading Supplier of Generics Internationally
  • 6.1.1 Sandoz Has A Wide Product Range An Important Core Competencies
  • 6.1.2 Sandoz Finally Benefits from Landmark Regulatory Decision Concerning Omnitrope
  • 6.1.3 Sandoz
• 6.2 Novartis' Sandoz Generics Division
  • 6.2.1 Background: Novartis Re-branded Its Generics Companies as Sandoz
• 6.3 Sandoz Has A Complex History From Establishment in 1886 to Present
• 6.4 Sandoz Has a Broad Product Range, Much of it Due to Acquisition of Generics Companies
• 6.5 Retail Generics Produces Finished Dosage Generic Forms
• 6.6 Sandoz Products: Retail Generics
• 6.7 Sandoz Products: Contract Biopharmaceuticals
• 6.8 Sandoz Products: Active Pharmaceutical Ingredients (API)
• 6.9 Sandoz Products: Product Intermediates
• 6.10 Sandoz Achieved Impressive Growth in 2006
• 6.11 Sandoz Will Achieve Strong Growth from 2008-2023
• 6.12 Sandoz Has Consolidated Its Market Position Through Acquisitions
  • 6.12.1 Sandoz Acquisition Post-Unification: Sabex
  • 6.12.2 Sandoz Acquisitions Post-Unification: Durascan
  • 6.12.3 Novartis Bought Hexal and Eon in $7bn Deal
• 6.13 Sandoz Receives Landmark US and European Regulatory Approval for Omnitrope in 2006
  • 6.13.1 Sandoz is Committed to The Emerging Field of Biosimilars - Generic Versions of Biopharmaceuticals
  • 6.13.2 Sandoz Filed Lawsuit Against FDA Ruling on Omnitrope
  • 6.13.3 Omnitrope Finally Received US and EU Approval in Early 2006
  • 6.13.4 Omnitrope is a Ground-Breaking Product in the Generics Sector - With Far Reaching Implications for the Market
• 6.14 Sandoz Invests in Low Cost Production
• 6.15 The Outlook 2008-2023- Being Part of Novartis Will Confer a Significant Competitive Advantage upon Sandoz
  • 6.15.1 Generics Market is Increasingly Competitive
  • 6.15.2 Sandoz Generic Segment Forecast 2008-2013 & 2023
  • 6.15.3 A Co-ordinated Strategy by Novartis Benefits Sandoz Greatly
  • 6.15.4 Sandoz Will Continue to Gain Prominence in the World Generics Market

7. Merck KGaA

• 7.1 Merck KGaA is a Leading International Producer of Generic Pharmaceuticals
  • 7.1.1 Merck - The Oldest Pharmaceutical Company in the World
  • 7.1.2 The Structure of the Merck KGaA
  • 7.1.3 The Generics Division Generates the Second Largest Sales in Merck' s Pharmaceuticals Business Sector
  • 7.1.4 Recent Developments in Merck Generics - Expansion of Core Business
• 7.2 Merck Generics Worldwide: the Merck KGaA group of companies
  • 7.2.1 Alphapharm - Australia
  • 7.2.2 Genpharm - Canada
  • 7.2.3 Merck South Africa
  • 7.2.4 Generics UK Limited
  • 7.2.5 Dey Incorporated
  • 7.2.6 Other Merck Companies Worldwide
• 7.3 Merck Generics Financials, 2006
  • 7.3.1 Merck Has Two Types of Generics Markets
  • 7.3.2 Generics Division Experiences The Highest Operating Results
  • 7.3.3 France Sees Generic Expansion
    • 7.3.3.1 Merck KGaA' s Spanish Market Experiences 47% Rise is Sales in 2006
  • 7.3.4 Merck KGaA Sales Declines in UK and Germany
  • 7.3.5 Integration of Dey as the Basis for Strategic Reorientation
  • 7.3.6 Sales Rise in The US and Canada
  • 7.3.7 Japan Experiences Sustained Revenue Growth
• 7.4 Merck KGaA Generics Segment Forecast, 2008-2013 & 2023
• 7.5 Merck Set to See Sustainable Generic Revenues Through Innovation of Product Life Cycle.
• 7.6 Major Developments in Merck Generics
  • 7.6.1 Innovative Products for High-Growth Indications
  • 7.6.2 Acquisition of NM Pharma from Pfizer
  • 7.6.3 Litigation and Other Claims Against Subsidiaries Resolved
  • 7.6.4 Merck To Leverage Its Position In Generic Respiratory Medicines
• 7.7 Merck' s Strategic Acquisition of Serono Will Drive Revenues in the Long-Term

8. Ratiopharm

• 8.1 Ratiopharm Is a Pioneer In Generics Pharmaceuticals
• 8.2 RatioPharm Generics Segment
• 8.3 International Sales Drives RatioPharm' s Revenue
• 8.4 Ratiopharm Leading Generics Sale
  • 8.4.1 Ratiopharm Regional Sales
  • 8.4.2 The US and Canadian Market
  • 8.4.3 Sales Distribution in Africa, Asia and Australian Markets, 2006
  • 8.4.3 Brazil Dominates Latin American Market
• 8.5 Ratiopharm Generic Segment Forecast 2008-2013 & 2023
• 8.6 Research And Development
  • 8.6.1 Ratiopharm Commences Biogeneric Projects
    • 8.6.1.1 Ratiopharm Enters Agreement With BioGeneriX and Neose
    • 8.6.1.2 Ratiopharm and Neose' s pegylated GCSF in Phase I Studies
• 8.7 Litigation and Agreements
  • 8.7.1 Ratiopharm Successfully Challenges Patent Protecting AstraZeneca' s Nexium (esomeprazole)
  • 8.7.2 Court Rules Against Ratiopharm' s Lipitor Challenge
• 8.8 Mergers and Acquisition
  • 8.8.1 Ratiopharm Acquires Magnafarma
  • 8.8.2 Ratiopharm Other Key Acquisitions

9 Watson Pharmaceuticals

• 9.1 History and Background to Watson Pharmaceuticals
• 9.2 Watson' s Generics Operations - A Large Product Portfolio Combined with A Strong Pipeline
• 9.3 Watson' s Strategy - The Development of Technologically Challenging and High Demand Products
• 9.4 Watson Business Strategy
• 9.5 Watson R&D Expenditure Expands
• 9.6 Watson' s Generic Product Range Accounts for Over Two Thirds of Net Sales
• 9.7 Watson' s Branded Products Profit Margins decline in 2006
• 9.8 Merger Between Watson and Andrx Drives Sales of Generic Products
• 9.9 Watson Generics Segment Forecast, 2008-2013 & 2023
• 9.10 Watson New Generic Product Launches
• 9.11 Watson Puerto Rico Site to Close as Cost Saving Strategy
• 9.12 Watson Agreements
  • 9.12.1 Agreement with GSK to Market Generic Zyban
  • 9.12.2 Agreement with Proctor & Gamble to Distribute Generic Macrobid
  • 9.12.3 Watson Terminates its Contract Sales Force Agreement With Ventiv Health
  • 9.12.4 Litigation Proceedings - Possible Adverse Effects on Company Finances
• 9.13. Watson Alliances and Collaborations
• 9.14 Watson' s Branded Pharmaceutical Will Contribute Significantly To Year-on-Year Sales Growth

10 Actavis

• 10.1 Actavis Leading European Generic Company
• 10.2 Actavis Products Portfolio And Strategic Business Markets
• 10.3 Actavis Market Segmentation Market Segmentation
  • 10.3.1. Actavis North American Markets Generates Highest Revenue
  • 10.3.2 Actavis CEEA Markets Performance
  • 10.3.3 Actavis WEMEA Markets
    • 10.3.3.1 Actavis Sales in The UK Grows By 6%
    • 10.3.3.2 Actavis Sales in Germany Declines
    • 10.3.3.3 Actavis Experiences Sales Declines in The Netherlands
    • 10.3.3.4 Actavis Scandanavian Market Grows
• 10.4 Actavis Third-Party Markets
• 10.5 Actavis Generics Segment Forecast, 2008-2013 & 2023
• 10.6 Actavis' Pipeline - Strong Product Development and Investment in Manufacturing
  • 10.6 1 Actavis' ANDA Filings Increases Significantly In Both US And EU
  • 10.6 2 Actavis Expands IP Project India and Iceland
  • 10.6 3 Actavis And Colotech Investigates Cancer Chemoprevention Medicines
• 10.7 Mergers, Acquisitions and Agreements
  • 10.7.1 Actavis Subsidiaries Expands
  • 10.7.2 Actavis Acquires Alpharma
  • 10.7.3 Actavis Establishes Global Hospital Business Unit (GHBU)
  • 10.7.4 Actavis To Expand In-licensing Deals
• 10.8 Actavis Is Strongly Positioned To Maintain Status As a Leading Generics Supplier

11. Barr Pharmaceuticals Inc

• 11.1 Barr Has Developed A Strong Range of Therapeutic Core Competencies
• 11.2 Barr' s Strengthens Portfolio Through Acquisition of Pliva
• 11.3 Barr Experiences Revenue Decline After Transition Period (July1-December 31)
• 11.4 Barr Products: Specialisation in Oral Contraception and HIV/AIDS
• 11.5 Barr Leading Products
• 11.6 Barr Key Financials
  • 11.6.1 Barr Generics Revenue
  • 11.6.2 Barr DDAVP (Desmopressin Acetate) 180 Days Marketing Exclusivity
  • 11.6.3 Barr Exclusive Provider of Diadanosine Delayed-Release Capsules.
  • 11.6.4 Court Denies Aventis Motion Against Barr' s Generic Allegra
  • 11.6.5 Barr Completes Isotrenioin Strength
  • 11.6.6 Barr Completes Claravis (Isotrenioin) Strength
  • 11.6.7 Barr Launches Leflunomide and Clonazepam Orally Disintegrating Tablets
• 11.7. Other Significant Barr Generic Launches
  • 11.7.1 Barr' s Aranelle Generic Version of Watson' s Tri-Norinyl
  • 11.7.2 Barr' s Kelnor Generic Version of Pfizer' s Demulen
  • 11.7.3 FDA Approves Barr' s Anagrelide Hydrochloride, Generic Version of Shire' s Agrylin
  • 11.7.4 Barr' s Duramed Expands Products With Shire' s Adderall IR
  • 11.7.5 Duramed To Market Seqsonique Extended-Cycle Oral Contraceptive In Leading Markets
  • 11.7.6 Barr Markets Generic Glucophage (metformin hydrochloride) For Diabetes
  • 11.7.7 Barr Investment In DTC Will Drive Products Growth
• 11.8 Pending Generic Patent Challenges
• 11.9 Barr Generics Segment Forecast, 2008-2013 & 2023
• 11.10. Proprietary Product Sales
  • 11.10.1 Barr' s ParaGard IU - A Non-Hormonal Contraceptive Proprietary Franchise
  • 11.10.2 Barr Doubles Women' s Health Sales Force
  • 11.10.3 Duramed' s Plan B OTC/Rx Emergency Contraceptive Receives Marketing Approval
  • 11.10.4 Duramed' s Proprietary Drugs Portfolio Boosted By Pliva Acquisition
• 11.11 Barr Invests Significantly in R&D of Generic And Proprietary Products
  • 11.11.1 Pliva Acquisition Strenghtens Barr R&D Pipeline Significantly
• 11.12 Barr' s Alliances
• 11.13 Litigations Facing Barr

12 Stada Healthcare

• 12.1 Stada A Leading European Generics Pharmaceutical Company
• 12.2 Stada Key Competencies
• 12.3 Stada Regional Sales
• 12.4 Stada US Markets Revenue Declines
  • 12.4.1 Stada Sales Reaches Newer Heights In The EU Market
  • 12.4.2 Stada' s Key EU Markets Contributes Significantly To Yearly Sales
• 12.5 Stada Generics Division
  • 12.5.1 Omeprazole - Stada' s Leading Product
• 12.6 Stada Branded Products
  • 12.6.1 Stada' s Proprietary Products Sales Growth Exceeds 20% In 2006
• 12.7 Stada Generics Segment Forecast, 2008-2013 & 2023
• 12.8 Stada Product Developments
• 12.9 Mergers, Acquisitions and Disposals
  • 12.9.1 Stada Acquires Significantly In 2007
• 12.10 Stada Initiates Biosimilar Projects
  • 12.10.1 Stada And Bioceuticals Arzneitmittel' s Biosimilar Pipeline.
  • 12.10.2 Stada Erythropoietin-Zeta (Epo-zeta)Receives Positive Opinion From EMEA

13. Mylan Laboratories

• 13.1 Mylan Was Originally a Packaging Company
• 13.2 Mylan Leading Therapeutic Classes
• 13.3 Mylan Records Highest Sale in US Market
  • 13.3.1 Mylan Product Sales Grows In the EU Market
• 13.4 Mylan' s Pharmaceuticals Product Porfolio Expands Significantly
• 13.5 Mylan' s Recent Financial Results
• 13.6 Mylan New Product Lauches To Drive Revenue Growth
  • 13.6.1 Mylan launched Amlodipine Besylate
  • 13.6.2 Mylan' s Oxybutynin ER Tablets
  • 13.6.3 Mylan' s Propranol hydrochloride ER capsules
  • 13.6.4 Mylan' s Other Major Launches
  • 13.6.5 Mylan Generics Segment Forecast, 2008-2013 & 2023
• 13.7 Mylan Increases R&D Expenditure
  • 13.7.1 Mylan Has A Strong Pipeline And Increased R&D Spending
• 13.8 Mergers, Acquisitions and Agreements
  • 13.8.1 Mylan Completes The Acquisition of Matrix Laboratory Outstanding Shares
  • 13.8.2 Mylan And Matrix Acquisition Will Intensify Antiretroviral Research
• 13.9 Legal Challenges on Products
  • 13.9.1 Omeprazole
  • 13.9.2 Lorazepam and Clorazepate

14. Apotex

• 14.1 Apotex Privately Owned Canadian Pharmaceutical Firm
• 14.2 Apotex Geneic Division
• 14.3 Apotex Experiences Continuous Growth Revenue
• 14.4 Apotex Regional Segmentation
  • 14.4.1 EU Region Apotex' s Third Largest Market
  • 14.4.2 Apotex' s Sales Growth Expands in Latin And Central American Markets
  • 14.4.3 Apotex' s Africa, Asia and Australia Generated The Least Sales In 2006
• 14.5 Apotex Leading Generic Drugs
  • 14.5.1 Sanofi-Aventis And BMS Secure Injunction Against Apotex' s Leading Drug Clopidogrel
  • 14.5.2 Apotex' s Omeprazole Sales Expands By A Significant Margin
• 14.6 Apotex Generics Segment Forecast, 2008-2013 & 2023
• 14.7 Apotex Research and Development
  • 14.7.1 Apotex R&D Investment Drives Sales By Over 20%
  • 14.7.2 Apotex R&D Projects Increases Innovative And Biotechnological Products
  • 14.7.3 Apotex Markets Amlodopine Generic Version of Pfizer' s Blockbuster Drug Norvasc
  • 14.7.4 Apotex Intensifies Haematology And Skin Replacement Research
• 14.8 Apotex Second Largest Mergers and Acquisitions
• 14.8.1 Apotex Acquires Lareq Pharma In Spain
• 14.9 Apotex Will Compete Strongly With The Top Five Leading Generic Companies

15. Conclusions

• 15.1 Generics Market Bubble-Patent Expiration $100bn Branded Products
• 15.2 Major Wave of Patent Expirations To Occur
  • 15.2.1 Patent expirations in 2006
  • 15.2.2 Patent Expirations in 2007
  • 15.2.3 Patent Expirations in 2008
  • 15.2.4 Patent Expirations in 2009
  • 15.2.5 Patent Expirations in 2010
  • 15.2.6 Patent Expirations in 2011
• 15.3 Generic Drugs Uptake in The US on the Rise
• 15.4 The UK has the Highest Generic Penetration by Value in All European Markets
• 15.5 The Expiration of Branded Patents is The Most Important Driver of Growth in The Sector
• 15.6 Characteristics of Differing Regulatory Systems Affect the Market for Generics
• 15.7 Biogenerics Are Becoming Increasingly Important
• 15.8 Teva Leads The Generic Sector
• 15.9 Consolidation to be Key Factor in Growth of Generic Industry
• 15.10 Strong Positioning in EU Market Will Be An Influential Factor For High Revenue
• 15.11 Generics Sector An Expanding Market With Lucrative Opportunities
• 15.12 Strategic Focus On Geographical Markets Will Be Key To Levarging Technological Innovations
• 15.13 Growing Presence of Automatic Substitution At Pharmacy Will Drive Generic Growth
• 15.14 Top Ten Generic Companies Will Experience Strong Revenues During 2008-2023
• 15.15 Device-Driven Products Holds Significant Revenue Potential For Generic Investors
• 15.16 Product Life-Cycle Management Will Be Crucial To Generic Revenue Growth

List of Tables

• Table 1.1 Top 10 Generic Comapnies, Generics Revenue ($bn) Forecast, 2008-2013,2018 & 2023
• Table 2.1 Sales of All Companies: Total Group and Generics Sales,2005-2006
• Table 2.2 Sales of All Companies: Total Group Sales,2005-2006
• Table 2.3 The Leading Generics Companies: Total Generic Sales Only, 2005-2006
• Table 3.1 Major Drugs Losing Patent Expiration in Near-Term
• Table 3.2 Branded and Generics Price Differentials in Selected Leading European Countries, 2006
• Table 3.3 The Top Ten US Generic Drugs by Revenue ($m) and Units
• Table.3.4 Prescription Number (m), 2004 Top 10 Generic Drugs, Dispensed by Prescriptions in the US, 2006
• Table 3.5 US Top Ten Generic Drugs as a Function of Combined Branded and Generic Drugs by Prescription Number (m) and Revenues ($m),2006
• Table 5.1 Top 20 Leading Pharmaceutical Companies,2006
• Table 5.2 Teva Net Sales, Net Income, 2006
• Table 5.3 Teva Subsidiaries, 2006
• Table 5.4 Sales ($m) by Geographical Area, 2004-2006
• Table 5.5 Sales ($m) by Business Division, 2004-2006
• Table 5.6 Principal Therapeutic Products Manufactured by Teva, 2007
• Table 5.7 Teva Pharmaceuticals: Top Five Therapeutic Classes, 2005-2006
• Table 5.8 Pharmaceuticals: Leading International Products, 2005-2006
• Table 5.9 Teva Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 5.10 R&D Investment by Teva, 2002-2006
• Table 5.11 Summary of R&D Pipeline
• Table 6.1 Sandoz Net Sales ($m) and Other Key Financials, 2006
• Table 6.2 Sandoz Net Sales (%) by Region, 2006
• Table 6.3 Sandoz Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 7.1 Sales of Pharmaceutical and Chemical Division, 2002-2006
• Table 7.2 Revenues of Pharmaceutical Businesses, 2002-2006
• Table 7.3 Merck KGaA Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 8.1 Revenues of Top Ten Selling Therapeutic Classes,2006
• Table 8.2 Revenues of Top Ten Selling Generics, 2006
• Table 8.3 Regional Sale Distribution, 2006
• Table 8.4 Sales Distribution in Major EU Markets, 2006
• Table 8.5 Sales Distribution in Canada and the US, 2006
• Table 8.6 Sales Distribution in Africa, Asia and Australian Markets, 2006
• Table 8.7 Sales Distribution in Latin and South American Markets, 2006
• Table 8.8 Ratiopharm Subsidiaries
• Table 8.9 Ratiopharm Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 9.1 Total Revenue including Major Operations, 2006
• Table 9.2 Net Revenue In Comparison With Other Operational Losses, 2006
• Table 9.3 Generic Segment Sales, 2006
• Table 9.4 Revenues of Branded Products Operations, 2006
• Table 9.5 R&D and Other Operating Expenditure, 2006
• Table 9.6 Watson Nephrology Product Portfolio
• Table 9.7 Watson Urology Product Portfolio
• Table 9.8 Pain Product Portfolio
• Table 9.9 Women' s Health Product Portfolio
• Table 9.10 Other Specialty Product Portfolio
• Table 9.11 Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 10.1 Actavis Total Revenue ($m) and Net Profit ($m), 2006
• Table 10.2 Actavis Leading Products in Major Markets, 2006
• Table 10.3 Actavis Revenue ($m) in Key Regions, 2006
• Table 10.4 Actavis Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 11.1 Barr Total Revenues and Net Earnings, 2003-2006
• Table 11.2 Comparison of the six months ended December 31 2006 and December 31, 2005
• Table 11.3 Barr Leading Products, 2006
• Table 13.4 Total Revenue of Oral Contraceptive, 2004-2006
• Table 13.5 Barr Patent Challenges and Valuation
• Table 11.6 Barr Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 11.7 Total Revenue of Proprietary Products, 2004-2006
• Table 11.8 Total Revenue of Proprietary Products, 2004-2006
• Table 12.1 Total Revenue ($m), Net Income ($m) and Operating Profit ($m), 2003-2006
• Table 12.2 Stada Core Business Revenues, 2006
• Table 12.3 Regional Sales Distribution, 2003-2006
• Table 12.4 Stada US Revenue ($m), 2002-2006
• Table 12.5 Regional Sales Distribution, 2003-2006
• Table 12.6 Revenues in Leading EU Markets, 2006
• Table 12.7 Revenue in Five Leading EU Markets, 2006
• Table 12.8 Revenue in Other Leading EU Markets, 2006
• Table 12.9 Revenue Top Five Leading Generic Products, 2006
• Table 12.10 Stada Top Five Branded Products Division Revenue, 2006
• Table 12.11 Stada Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 12.12 Stada M&A Operations, 2006
• Table 12.13 Stada M&A Operations, 2006
• Table 13.1 Total Revenue ($m) and Profit ($m) for Mylan
• Table 13.2 Total Revenue ($m) of Mylan Leading Therapeutic Classes
• Table 13.3 Mylan' s Leading Products, 2006
• Table 13.4 Mylan Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 13.5 Mylan' s R&D Investment, 2003-2007
• Table 14.1 Apotex Revenues, 2004-2007
• Table 14.2, Market Share of Apotex Leading Therapeutic Classes, 2006
• Table 14.3 Apotex Geographical Revenues, 2006
• Table 14.4 Apotex Revenues in US and Canada, 2006
• Table 14.5 Apotex Revenues in Key EU Markets, 2006
• Table 14.6 Apotex Revenues in Key Latin American Markets, 2006
• Table 14.7 Apotex Revenues in Key Central American Markets, 2006
• Table 14.8 Apotex Revenues in Key Africa, Asia& Australia Markets, 2006
• Table 14.9 Apotex Revenues For Leading Drugs, 2006
• Table 14.10 Apotex Revenues For Top Five Drugs, 2006
• Table 14.11 Apotex Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Table 15.1 Near-term Patent Expiration ,207-2009

List of Figures

• Figure 1.1 Top 10 Generic Comapnies, Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 2.1 Sales 2004-2006 All Companies: Total Group Sales
• Figure 2.2 Market Share of Sales of All Companies: Total Group Sales,2006
• Figure 2.3 The Leading Generics Companies: Total Generic Sales Only, 2005-2006
• Figure 2.4 Market Share of Sales of All Companies: Generic Sales Only, 2006
• Figure 3.1 Per Capita Growth Rate for National Health Expenditure Vs Prescription Drugs Over Four Decades
• Figure 5.1 Teva Net Sales, 2006
• Figure 5.2 Teva Net Income, 2006
• Figure 5.3 Sales ($m) by Geographical Area, 2004-2006
• Figure 5.4 Sales ($m) by Business Division, 2004-2006
• Figure 5.5 Teva Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 5.6 R&D Investment by Teva, 2002-2006
• Figure 6.1 Sandoz Net Sales ($m) and Other Key Financials, 2006
• Figure 6.2 Sandoz Net Sales (%) by Region, 2006
• Figure 6.3 Sandoz Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 7.1 Sales of Pharmaceutical and Chemical Division, 2002-2006
• Figure 7.2 Revenues of Pharmaceutical Businesses, 2002-2006
• Figure 7.3 Market Share of Merck KGaA Businesses, 2006
• Figure 7.4 Regional Revenues of Generic Pharmaceuticals, 2006
• Figure 7.5 Regional Market Share of Generic Pharmaceuticals, 2006
• Figure 7.6 Merck KGaA Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 8.1 Market Share of Ratiopharm Top Ten Selling Therapeutic Classes,2006
• Figure 8.2 Market Share of Ratiopharm Top Ten Selling Generics, 2006
• Figure 8.3 Regional Sale Distribution, 2006
• Figure 8.4 Sales Distribution in Major EU Markets, 2006
• Figure 8.5 Sales Distribution in Canada and the US, 2006
• Figure 8.6 Sales Distribution in Africa, Asia and Australian Markets, 2006
• Figure 8.7 Market Share Distribution in Latin American Markets, 2006
• Figure 8.8 Ratiopharm Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 9.1 Total Revenue Including Major Operations, 2006
• Figure 9.2 Net Revenue In Comparison With Other Operational Losses, 2006
• Figure 9.3 Market Share of Branded Products Vs Generics
• Figure 9.4 Watson' s R&D Expenditure, 2002-2006
• Figure 9.5 Generic Segment Sales, 2006
• Figure 9.6 Revenues of Branded Products Operations,2006
• Figure 9.7 R&D and Other Operating Expenditure, 2006
• Figure 9.8 Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 9.9 Watson ANDA Submission, 2002-2006
• Figure 9.10 Watson ANDA Pending Approvals 2002-2006
• Figure 10.1 Actavis Total Revenue ($m) and Net Profit ($m), 2006
• Figure 10.2 Actavis Regional Market Share Distribution
• Figure 10.3 Market Share of Actavis Leading Products in Major Markets, 2006
• Figure 10.4 Actavis Revenue ($m) in Key Regions, 2006
• Figure 10.5 Actavis Market Share in CEEA Market 2006
• Figure 10.6 Actavis Market Share in WEMEA Market, 2006
• Figure 10.7 Actavis Third Party Division Market Share Market, 2006
• Figure 10.8 Actavis Third Party Division Regional Market Share Market, 2006
• Figure 10.9 Actavis Watson Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 11.1 Barr Total Revenues and Net Earnings, 2003-2006
• Figure 11.2 Barr Leading Products, 2006
• Figure 11.3 Total Revenue of Oral Contraceptive, 2004-2006
• Figure 11.4 Barr Generic Products Revenues ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 11.5 Total Revenue of Proprietary Products, 2004-2006
• Figure 11.6 Total Revenue of Proprietary Products, 2004-2006
• Figure 12.1 Net Income ($m) and Operating Profit ($m), 2003-2006
• Figure 12.2 Stada Core Business Revenues, 2006
• Figure 12.3 Market Share of Stada Core Business Revenues, 2006
• Figure 12.4 Regional Sales Distribution, 2003-2006
• Figure 12.5 Market share of Regional Sales Distribution, 2006
• Figure 12.6 Stada US Revenue ($m), 2002-2006
• Figure 12.7 Stada Market Share in Six Major Regions, 2006
• Figure 12.8 Market Share Revenues in Leading EU Markets, 2006
• Figure 12.9 Revenue in Five Leading EU Markets, 2006
• Figure 12.10 Revenue in Other Leading EU Markets, 2006
• Figure 12.11 Stada Generic Division Revenue, 2003-2006
• Figure 12.12 Revenue Top Five Generic Products, 2006
• Figure 12.13 Stada Branded Products Division Revenue, 2003-2006
• Figure 12.14 Market Share of Stada' s Top Five Branded Products Division Revenue, 2006
• Figure 12.15 Stada Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 12.16 Stada M&A Operations, 2006
• Figure 12.17 Stada M&A Disposals Revenue, 2006
• Figure 13.1 Mylan Total Revenue ($m) and Profit ($m),2003-2006
• Figure 13.2 Total Revenue ($m) of Mylan Leading Therapeutic Classes
• Figure 13.3 Market Share Distribution of Mylan' s Leading Therapeutic Classes
• Figure 13.4 Total Revenue Distribution in Major Geographical markets, 2006
• Figure 13.5 Market Share of Mylan' s Leading Products, 2006
• Figure 13.6 Mylan Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023
• Figure 13.7 Mylan' s R&D Investment, 2003-2007
• Figure 14.1 Apotex Revenues, 2004-2007
• Figure 14.2 Market Share of Apotex Leading Therapeutic Classes, 2006
• Figure 14.3 Apotex Geographical Revenues, 2006
• Figure 14.4 Market Share of Apotex Revenues in US and Canada, 2006
• Figure 14.5 Market Share of Apotex Revenues in Key EU Markets, 2006
• Figure 14.6 Market Share of Apotex Revenues in Key Latin American Markets, 2006
• Figure 14.7 Apotex Revenues in Key Central American Markets, 2006
• Figure 14.8 Market Share of Apotex Revenues in Key Africa, Asia & Australia Markets, 2006
• Figure 14.9 Apotex Revenues For Leading Drugs, 2006
• Figure 14.10 Apotex Revenues For Top Five Drugs, 2006
• Figure 14.11 Apotex Generics Revenue ($bn) Forecast, 2008-2013, 2018 & 2023

Companies mentioned in this report:

• Abbott Laboratories
• Abrika
• Abz Pharma
• Actavis
• Active Biotech
• Akzo Nobel
• Alcon Labs
• Allergan
• Alphapharm
• Alza
• Amgen
• Amide
• Anchen Pharmaceuticals
• Andrx
• Apotex
• Apothecon
• AstraZeneca
• Aventis
• Azupharma
• Balkanpharma
• BASF Pharma
• Bayer
• Bioceuticals Arzneitmittel
• Biochemie
• Biogen Idec
• Bioval
• Boehringer Ingelheim
• Bristol- Myers Squibb
• Cajavec
• Cell Pharma
• Celltech
• Cephalon
• Cipla
• Colotech
• Croma
• CT Arzneimittel
• Daiikyi Sankyo
• Dey
• Duramed
• Durascan
• Eisai
• Elan
• Eli Lilly
• Elite
• Eon Labs
• Esteve Quimica S.A
• Eurogenerics
• FEI Women' s Health LLC
• Ferd Schulze
• Forum Bioscience
• Geneva Pharmaceuticals
• Genevar
• Genpharm
• GlaxoSmithKline
• GlycoSciences
• Helvepharm
• Hemovet
• Hexal AG
• Hospira
• IMPAX
• IntelliPharmaCeutics
• Ivax
• Janssen
• Johnson & Johnson
• King Pharmaceuticals
• Labinca
• Lagap Pharmaceuticals
• Lareq Pharma
• Lundbeck
• Magnafarma BV
• Markiz
• Martec
• Matrix Docpharma
• Matrix Laboratories
• Meph
• Merck & Co
• Merck Génériques
• Merck KGaA
• Merckle
• Multipharma
• Mylan
• Mylan Technologies Inc
• NM Pharma
• Nycomed
• Organon
• Ortho Biotech
• ParaGard
• Penederm
• Pfizer
• Pharmacia
• PharmaCoDane Aps
• Plantex
• Pliva
• PriceWaterHouseCooper
• Proctor & Gamble
• Progen Biotechnik
• Quimica Farmaceutica
• Ratiopharm
• Roche
• Rolab
• Sabex
• Sandoz
• Sanmar
• Sanofi-Aventis
• Savient
• Scandharm
• Schering-Plough
• Sekhsaria Chemical Limited
• Serono
• Servipharm
• Shire
• Sigma
• Sindan
• Solvay
• Somerset Pharma
• Stada
• Takeda
• Technilab Pharma
• Teva
• Topgen
• UCB
• UDL Laboratories
• US Department of Defence
• Ventiv Health
• Warner Chilcott
• Watson
• Weizmann Institute of Science
• WHO
• Wyeth
• Xanodyne
• Zambon
• Zio Zdorovje